ObjectiveThis study aimed to evaluate the efficacy of rituximab (RTX) in the treatment of anti-glomerular basement membrane disease (anti-GBM disease) and to analyze the clinicopathological factors associated with long-term renal outcomes.MethodsThis study enrolled a total of 66 patients with confirmed anti-GBM disease. Patients were divided into two groups: the control group (n=52) received conventional therapy, including plasma exchange, glucocorticoids, and cyclophosphamide as clinically indicated, and the RTX group (n=14) received RTX in addition to the same conventional therapy.
The baseline characteristics, treatment responses, and long-term outcomes were compared between the two groups.ResultsThe baseline clinical and pathological characteristics were balanced and comparable between the two groups. Although the RTX group demonstrated only numerical advantages in the absolute rate of dialysis independence (50.0% vs.
21.05%, p=0.107) and the 3-year ESRD incidence (42.86% vs. 63.46%, p=0.223), the median time to dialysis independence was significantly shorter in the RTX group compared to the control group (26 vs.
41 days, p=0.009).
Frontiers in Immunology published a clinical update in Infectious Disease on 11 May 2026.
The item focuses on Rituximab is associated with accelerated dialysis independence in anti-glomerular basement membrane disease: a retrospective cohort analysis of renal survival.
Review the original article for the full source wording and details.